<SEC-DOCUMENT>0001628280-21-012055.txt : 20210611
<SEC-HEADER>0001628280-21-012055.hdr.sgml : 20210611
<ACCEPTANCE-DATETIME>20210611062121
ACCESSION NUMBER:		0001628280-21-012055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210611
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210611
DATE AS OF CHANGE:		20210611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		211009915

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20210611.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:f89a66cd-e988-423f-a83c-52fb2b628e3d,g:f7e3462f-ac2b-4513-bc67-487304c8cf53,d:bd5fef53e7a54ba5bdc495ac6d6cbe52--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20210611</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml80L2ZyYWc6ZTJmNGQzYzk3NDhlNDEwNGIzYWMxMDM3NDljNmNjODYvdGFibGU6ZWI2YjU4ZTQxN2M5NDkzMzkyYTYzZGU5OTdhNWM5ZWEvdGFibGVyYW5nZTplYjZiNThlNDE3Yzk0OTMzOTJhNjNkZTk5N2E1YzllYV8wLTEtMS0xLTA_f32c898b-4fab-4955-9d30-16674eeef997">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml80L2ZyYWc6ZTJmNGQzYzk3NDhlNDEwNGIzYWMxMDM3NDljNmNjODYvdGFibGU6ZWI2YjU4ZTQxN2M5NDkzMzkyYTYzZGU5OTdhNWM5ZWEvdGFibGVyYW5nZTplYjZiNThlNDE3Yzk0OTMzOTJhNjNkZTk5N2E1YzllYV8xLTEtMS0xLTA_538af006-2d42-4311-bfc1-bfb0b2bb99f2">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20210611.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icd559cc0f512485fad1a52199f605202_D20210611-20210611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-11</xbrli:startDate><xbrli:endDate>2021-06-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibd5fef53e7a54ba5bdc495ac6d6cbe52_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.988%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MjIwYjJiZWZkNjM4NDBmY2I0ZjI2MTcwYjU4YTYxYjgvdGFibGVyYW5nZToyMjBiMmJlZmQ2Mzg0MGZjYjRmMjYxNzBiNThhNjFiOF8wLTEtMS0xLTA_1724a181-2472-4467-935f-90a7e498282d">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Data of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18yMTg_7eee5b7d-46bf-4657-8de7-e4a56b9b97ac">June 11, 2021</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OGJmMzJhMzljODM4NDkxYmIzMDU4OTU0OTdlN2NlMGQvdGFibGVyYW5nZTo4YmYzMmEzOWM4Mzg0OTFiYjMwNTg5NTQ5N2U3Y2UwZF8xLTAtMS0xLTA_c96eb2d8-2850-4153-a389-8ff52a6ffb32">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTAtMS0xLTA_239d9523-d848-41f7-965d-87cf7390a09f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTItMS0xLTA_4defbf91-01f8-440d-a1fa-9b4cc325bd32">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTQtMS0xLTA_d9489976-1e33-4574-a075-054488ab3159">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8wLTAtMS0xLTA_bfe51f4c-dc97-435e-a3c9-93d71ebe5252">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8wLTEtMS0xLTA_4bc13424-ccd0-4827-92c0-3598b0c76d64">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTAtMS0xLTA_4e5896f7-9e1b-4bbc-a3d4-a3440e313a1d">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTEtMS0xLTA_6d6097b2-297e-4f8b-98ca-b397c5024a0d">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTMtMS0xLTA_c0908c03-f3b2-4fb6-b372-24b81a917507">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDYy_0663326f-1ee4-4873-957e-0ea34c9dc263">857</ix:nonNumeric>) <ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY3_8f48d04c-0e32-496c-b004-ee36e45e409e">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY5_2cef6116-a1ad-48fe-9944-d17b644e56d9">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY0_41248245-eedb-4642-a324-ce9f16260566">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcx_1d5f414a-3715-418b-9d9a-d2672198bfbb">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcy_324a9b4e-d402-4d34-bc37-d2fb2937a475">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTAtMS0xLTA_a554e900-945e-4a21-b5e8-86fe26289bf0">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTItMS0xLTA_54f9ad6e-5a20-4691-b3a2-a60ea5d96104">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTQtMS0xLTA_7a92a998-5a82-4cec-ae56-21a710cb4b48">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).          Emerging growth company&#160;<ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcz_b40ef987-974e-490e-8f53-65789b9c6be6">&#9746;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act&#160;&#160;<ix:nonNumeric contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY2_e70a6b6c-af86-4940-a045-1c3182701a7d">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibd5fef53e7a54ba5bdc495ac6d6cbe52_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Events</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2021, X4 Pharmaceuticals, Inc. issued a press release announcing the presentation of positive data from its ongoing phase 1b clinical trial of mavorixafor in Waldenstr&#246;m&#8217;s macroglobulinemia at the 26th Congress of the European Hematology Association (EHA 2021). The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleasejune112021.htm">Press release dated June 11, 2021</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibd5fef53e7a54ba5bdc495ac6d6cbe52_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  June 11,  2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleasejune112021.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifad6169615014138b02fa2a478e417f1_58"></div><div style="min-height:90pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EX-99.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenstr&#246;m&#8217;s Macroglobulinemia at EHA 2021</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenstr&#246;m&#8217;s patients&#59; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">At 6 months, patients achieved median IgM level reductions of 60%-75%, with <br>one patient achieving normal IgM, and two of four patients (50%) had &#62;50% reduction <br>in IgM from baseline </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">e-Poster now available online&#59; pre-recorded presentation by lead author Dr. Steven Treon <br>available to EHA conference attendees</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Conference call and webcast today at 7&#58;00 am ET with X4 management and <br>poster co-author Dr. Christian Buske </font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BOSTON, Mass., June 11, 2021 &#8212;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">X4 Pharmaceuticals, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Nasdaq&#58; XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced positive preliminary efficacy and safety data from its ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, in Waldenstr&#246;m&#8217;s macroglobulinemia patients with both MYD88 and CXCR4 mutations. These data are included in a poster published today at this year&#8217;s European Hematology Association (EHA) Annual Congress.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are very pleased to present this exciting first look at the data from our ongoing Phase 1b trial in double-mutation Waldenstr&#246;m&#8217;s patients,&#8221; said Diego Cadavid, M.D., Chief Medical Officer of X4 Pharmaceuticals. &#8220;Despite still being in the low- and mid-dose ranges of mavorixafor, we are already seeing robust decreases in IgM levels &#8211; an important signal of clinical response &#8211; showing the potential benefit for mavorixafor in combination with ibrutinib. The combination therapy is demonstrating good tolerability and promising results across additional pharmacodynamic parameters, including increases in total hemoglobin and mobilization of white blood cells. We look forward to presenting longer-term data and an expanded data set from this trial later in the year.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;While ibrutinib has significantly advanced the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia, we have observed that there remains a clinical unmet need for patients with concurrent CXCR4 and MYD88 mutations,&#8221; said Steven Treon, M.D., Ph.D., FACP, FRCP, Director of the Bing Center for Waldenstr&#246;m's Macroglobulinemia at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and the poster&#8217;s lead author. &#8220;I am encouraged by the preliminary safety and efficacy data from the ongoing combination trial of ibrutinib and mavorixafor in this difficult-to-treat patient population and look forward to continuing this important research.&#8221;</font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EX-99.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Highlights of the Preliminary Low- and Mid-Dose Phase 1b Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">As of April 15, 2021, 8 patients had been enrolled in the Phase 1b clinical trial with a median duration of treatment of 156 days&#59; data presented are primarily from patients in Cohort A who received low- and mid-range doses of mavorixafor plus ibrutinib&#59; 4 patients were treated for more than six 28-day cycles.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Mavorixafor exposures tracked with sustained and dose-dependent increases in white blood cell counts, confirming target engagement and mavorixafor mechanism of action.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">All patients (100%) experienced reductions in serum IgM and no patients&#8217; disease progressed while on treatment.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">At 6 months, mavorixafor plus ibrutinib showed signs of meaningful reductions in IgM versus comparable, previously published data of ibrutinib monotherapy in double-mutation patients&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Patients achieved median reductions of 60%-75% in serum IgM levels normalized to baseline&#59; this compares to published ibrutinib monotherapy reductions of 38%-45% in double-mutation patients. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">2 out of 4 patients (50%) had &#62;50% reduction in serum IgM from baseline&#59; comparable reductions have been reported in only 28%-38% of double-mutation patients on ibrutinib monotherapy.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">One patient achieved IgM levels within normal range, a key criterion for a complete response.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">All patients with hemoglobin levels below normal at baseline had increases during treatment, with a median change in hemoglobin of &#62;20 g&#47;L, approaching normal levels and suggesting reduction in cancer burden in the bone marrow.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Mavorixafor and ibrutinib exposures were consistent with previous single-agent studies, suggesting no drug-drug interactions.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Data suggest that mavorixafor plus ibrutinib is well tolerated with no serious adverse events reported.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Patient enrollment and dose escalation to the highest mavorixafor dose (600 mg) continues.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The e-poster (EP784) entitled&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Preliminary Clinical Data From a Phase 1b Study of Mavorixafor and Ibrutinib in Patients With Waldenstr&#246;m&#8217;s Macroglobulinemia With MYD88 and CXCR4 Mutations&#8221; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">is now available on the </font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">X4 corporate website</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Conference attendees can access an accompanying audio presentation by Dr. Treon on the</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Congress website</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">X4 will host a conference call and webcast at 7&#58;00 am ET today that </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will include presentations by X4 senior executives and a &#8220;Fireside Chat&#8221; and Q&#38;A with poster co-author Christian Buske, M.D., Director of the Institute of Experimental Cancer Research and Attending Physician, Senior Consultant at the University Hospital of Ulm, and Founder and Coordinator of the European Consortium for Waldenstr&#246;m&#8217;s Macroglobulinemia. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The conference call can be accessed</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by dialing (866) 721-7655 (domestic) or (409) 216-0009 (international), followed by the conference ID&#58; 4492859. The live webcast will be accessible on the Events &#38; Presentations page of the company&#8217;s website at </font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investors.x4pharma.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The conference call slide deck will be made available upon completion of the event and the webcast replay will be available approximately two hours after the completion of the event on X4&#8217;s website.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Phase 1b clinical trial is being conducted with the support of AbbVie Inc. and The Leukemia &#38; Lymphoma Society&#8217;s Therapy Acceleration Program&#174; (LLS TAP).</font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EX-99.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Waldenstr&#246;m&#8217;s Macroglobulinemia and Associated CXCR4 Mutations</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Waldenstr&#246;m&#8217;s macroglobulinemia is a rare B-cell lymphoproliferative disorder characterized by increased immunoglobulin M (IgM). Greater than 90% of patients with Waldenstr&#246;m&#8217;s have acquired mutations in the MYD88 gene, with a subset (30%&#8211;40%) also having mutations in chemokine receptor CXCR4. The presence of the CXCR4 mutation is associated with greater cancer burden, higher serum IgM levels, and increased risk of developing a serious emergent condition called symptomatic hyperviscosity syndrome. Importantly, the presence of CXCR4 mutations has been shown to negatively impact patients&#8217; response to ibrutinib (a BTK inhibitor), as manifested by delayed response, inferior depth of response, and&#47;or shorter progression-free survival.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Mavorixafor and the Phase1b Clinical Trial in Waldenstr&#246;m&#8217;s Macroglobulinemia</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mavorixafor is an oral small-molecule antagonist of the CXCR4 receptor with a demonstrated ability to inhibit binding of its ligand, CXCL12&#59; this inhibition of CXCR4 has been shown to sensitize Waldenstr&#246;m&#8217;s cells with both MYD88 and CXCR4 mutations to BTK antagonists, such as ibrutinib. The ongoing Phase 1b, open-label, multicenter, single-arm study (</font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NCT04274738</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) examines intra-patient dose escalation, safety, pharmacokinetics, and pharmacodynamics of mavorixafor in combination with ibrutinib in patients with a diagnosis of Waldenstr&#246;m&#8217;s macroglobulinemia and confirmed MYD88 and CXCR4 genetic mutations. In the study, patients are initiated on oral, once-daily doses of ibrutinib 420 mg and mavorixafor 200 mg (low dose)&#59; in Cohort A, patients are escalated to 400 mg mavorixafor (mid-dose) after 28 days if fewer than two dose-limiting toxicities are observed at the low dose&#59; in Cohort B, patients are escalated from 200 mg to 400 mg and finally to 600 mg (high dose) after each dose level is deemed tolerable. Patients are followed for adverse events and change from baseline in serum IgM and hemoglobin, pharmacokinetics, and pharmacodynamic markers, including peripheral white blood cell counts (WBCs).</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About X4 Pharmaceuticals</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company&#8217;s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials &#8211; in combination with ibrutinib in patients with Waldenstr&#246;m&#8217;s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit </font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.x4pharma.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EX-99.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">statements regarding the clinical development of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia and primary immunodeficiencies, the potential benefits of mavorixafor in the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia or any other indication, and the availability and timing of future data from X4&#8217;s ongoing clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes, the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials, the potential adverse effects arising from the testing or use of mavorixafor or other product candidates, and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors and Media&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>Daniel Ferry<br>Managing Director<br>LifeSci Advisors<br></font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">daniel&#64;lifesciadvisors.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>(617) 430-7576</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">M&#243;nica Rouco Molina<br>Senior Account Executive<br>LifeSci Communications<br></font><font style="background-color:#ffffff;color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mroucomolina&#64;lifescicomms.com</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20210611.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f89a66cd-e988-423f-a83c-52fb2b628e3d,g:f7e3462f-ac2b-4513-bc67-487304c8cf53-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20210611" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20210611">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210611_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210611_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20210611_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f89a66cd-e988-423f-a83c-52fb2b628e3d,g:f7e3462f-ac2b-4513-bc67-487304c8cf53-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_6b98e016-415f-42cc-9be7-5e3de71d3d02_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3ac19ec2-2a75-4589-a2d1-81055705c293_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_409257f7-17b9-4e55-8628-df4ede05c21a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5d157193-5949-4e93-aca3-48ee5b44dd17_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f299a5f3-8aa7-44ce-989e-72bb62809753_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a43af92d-771f-4b66-94c8-c3233e113204_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b7ef9a38-4ad6-414d-9d65-7cd3e726eb8d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_30bb5c36-d8f8-4dbf-8512-d26bdb9ef713_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c78bf4bc-1c84-46fd-9c2a-967a8aa5abde_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dfca6360-2056-49cd-89c4-95d552ed7fb2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e7522dfc-9b8e-4a97-b935-215ef2296e9c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_21231a25-de69-4e8d-8e36-8a65bce3b76d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3fa2cf04-9439-41bc-8c84-9702ca415d23_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f5b0e87a-cfd4-4d51-b7ad-ea9d03f570d8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_34002477-02a4-4319-b2ff-ea2bb858112f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_249b763b-c060-4cbf-8b96-5cab5a580b4c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2ae5a597-26ac-4e49-bc77-d821c615fd00_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5104c144-a6ff-4c93-a148-714c6d4543b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1c1cc60b-5c38-4000-97e4-ae5a7534e0bb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6ba00a56-18d1-4c32-ab95-6bb74dba03d7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_293761b1-9585-4f0d-b9ce-0e5d26d9796b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_210eeb06-ae68-407b-9f66-f188ba26ef4e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5ec20a70-261f-4e73-a3c2-9d03cb5c4604_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_437a9be0-266c-472c-9632-88a70e3abcc3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20210611_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f89a66cd-e988-423f-a83c-52fb2b628e3d,g:f7e3462f-ac2b-4513-bc67-487304c8cf53-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20210611.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e26e8f8b-c963-44cb-8def-5b2d62ac588d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_DocumentType_e26e8f8b-c963-44cb-8def-5b2d62ac588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b34e49b-dfb4-46b5-8a71-05b70f352d7d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_DocumentPeriodEndDate_2b34e49b-dfb4-46b5-8a71-05b70f352d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ae96e1a1-16a0-4919-9e77-74e014540e47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityRegistrantName_ae96e1a1-16a0-4919-9e77-74e014540e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_96fe0bf4-f70f-416b-9d7d-0eb92f6e2a8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_96fe0bf4-f70f-416b-9d7d-0eb92f6e2a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a5d353d8-a6c2-4c43-8693-0d952c775e15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityFileNumber_a5d353d8-a6c2-4c43-8693-0d952c775e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f6ce10d2-1405-48c7-b272-6efcec741957" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityTaxIdentificationNumber_f6ce10d2-1405-48c7-b272-6efcec741957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_936cad8f-9296-4fb6-a3e6-5b6578636ed9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityAddressAddressLine1_936cad8f-9296-4fb6-a3e6-5b6578636ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_cbc0d76c-25a0-4a0c-a48b-06fde3ce7e8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityAddressAddressLine2_cbc0d76c-25a0-4a0c-a48b-06fde3ce7e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_06d469bb-5e6f-4398-bd95-aaba946982ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityAddressCityOrTown_06d469bb-5e6f-4398-bd95-aaba946982ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0cfd5bb0-25a6-464a-83c5-da73d3dad490" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityAddressStateOrProvince_0cfd5bb0-25a6-464a-83c5-da73d3dad490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_81a316d1-915e-47c4-8e0f-0aec6dc2314e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityAddressPostalZipCode_81a316d1-915e-47c4-8e0f-0aec6dc2314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_12d44ae0-68cd-430c-8e1f-338114cb51bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_CityAreaCode_12d44ae0-68cd-430c-8e1f-338114cb51bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_102bd543-882c-49f4-8cd4-ab831515abad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_LocalPhoneNumber_102bd543-882c-49f4-8cd4-ab831515abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d150f757-baf4-4d51-ba16-1d5986607de6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_WrittenCommunications_d150f757-baf4-4d51-ba16-1d5986607de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_111c9407-5774-49d0-9e89-81f9a353804f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_SolicitingMaterial_111c9407-5774-49d0-9e89-81f9a353804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d3884c87-936b-4e58-b035-8e3bc031d9fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_PreCommencementTenderOffer_d3884c87-936b-4e58-b035-8e3bc031d9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8cf0370e-fac0-4997-9316-8aff77805dd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8cf0370e-fac0-4997-9316-8aff77805dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_619d630c-8d7d-4082-b39e-6dfc236a726a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_Security12bTitle_619d630c-8d7d-4082-b39e-6dfc236a726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f2b49e46-484e-4c6a-bd96-64a43437874a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_TradingSymbol_f2b49e46-484e-4c6a-bd96-64a43437874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_592e06c1-01f2-4d22-9a61-8a8ba841ebba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_SecurityExchangeName_592e06c1-01f2-4d22-9a61-8a8ba841ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b71ac6c2-4cc4-4b53-88f3-2b7bd6adce0d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityEmergingGrowthCompany_b71ac6c2-4cc4-4b53-88f3-2b7bd6adce0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_7a26cd96-7be7-4225-a1e8-521994c38faa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityExTransitionPeriod_7a26cd96-7be7-4225-a1e8-521994c38faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7f31fd07-c632-47f9-9925-8589cee94403" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_EntityCentralIndexKey_7f31fd07-c632-47f9-9925-8589cee94403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a8661ca3-f8c3-4ec0-8281-e9b9a0918dd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_147be8c6-7069-487b-9fef-c93883b741fd" xlink:to="loc_dei_AmendmentFlag_a8661ca3-f8c3-4ec0-8281-e9b9a0918dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MO[2P].6#J (YJX;^4>W5I$WG>DUW^!V&YOJHP+_?72_=!QSNAJ=G5:#$L/[
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MR(G30HFK!^N'ZDT*DIX[429;=IW0:NBPGV^LC?Y-HBG[JUJT'0LE-LW;A?U
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M!ZM;->)&?0&1)L/EPSL2YE1*2+:T:U#>+*A1G5S?"[5XB9!>1/^8BD7FEE*
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M9T.[E:]A: U+.J_HP:.%6HC%ACRL>> $/"%Y! YZ>)Z-@Z/R<7F3W._N/WM
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MCI GH^!VEC9J"/IJ%>0(_Z5(56,3YAF0^T2@O\=MP/2$QEN8(6Q,SR](2<>
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MVIZ*9HT$4*@6;S6M0)H2\J=.@90 !\14&9W)FHV,*<Q2L9R:WF'-TR=C&#J
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MV$\8":\!M#>09Z/R%^_P%K?9^A;F@T@V1:?-/'J\6-XKJI.B]O[+&O<6"$5
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M:$6B&A6A QZP(7'!&FT9'--GQ3,+/&)?C7>/=Q B/E[7H=K2\ZN8WL7/$47
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MN/G.N^3Z:I%TCPE1<BY=NZZZ*%DO!,Y209C"(A9XP+%#EV"[#0*58'QC4;
MP;CC4^8-V(F% Z)J^9:Q&-O37WAPY8NU\)>ESWA*@> V//.3GQ]\X()+Z]H1
MOA#'%\OL V$*%8L&4''YLU[:<]!]/ES:EI!7X[T%/+8G" .FJV^Y8W#JQX<Q
M?DI%](. ]QX B!>^!X"!KS7#)1Z?/?RD#]?XZ"EK+AY<^<7UU:T\"0B;FV$N
MQ?V#$\_\1+5TGUQ $4 "(W/+L\%=+"XL5(,7^/[!"R\=G%;FQ&,N;EY_3V_B
M))<O<+SKOOL'?_W13]>UVUUWUKU]>]47;Z^9WJ,2,)<+A.,8DJ0X2IS]25$F
MEUBZ]KK^R"D@=^+A#>-%"KY3V/0YW=$)PFA5@##K2KSKRIO7U\7I$1/CLOG0
M19<7X7-*M8()6UHP"X?[ZXKR>:ZH68$P]]T9%UU6A;3WA?O/\X3G[5?[0?B]
MYYR_6T@HXV+K4A\(XPF!@2]BL<$7#[<GZX  %=\DC/0=<+_F+>^KO&,M$4KC
M0)C0!.* 6-(( .FZ]0A=5A)^_.;+CWR,RWU:$ 9ZW,!['73< D#$HU_ #P#H
M?SVR-")A1S\O*XH! 'C182=6H?JTQFO@=S&WBRY?6X&*HL9U: U(HI&-[2=K
MV]H!>I2.+@BS@BE _D^\6[RW/0?=1YN ]Y$F1+(]01A?>#O$SV\JZ\8XHQ]B
MG,9O'5%&K WSQAH#V.+@\5G?DR2D'6MYF."X. BS.H5@A#^ /I W/HJ+=P$:
MX&:= EGMXX]L? JB.?&8"_D4?6#$2ORGPB?*$D6+0M0'PJS.]Q?%3J+:J$S_
MY0)A?:*H.OD@X>R7]OZS.F8RZ?FO.KKN 3)+7\QQ/)0S,>#@NR0X\Y>)60G"
M:%6 ,$V:&[7/2B0<9%KN7H0C2P_06?"$.8'SM>9HRTJ"<!0D<-Q!,@\!\;1&
M0?  8 \A 1@D#!%VQK*YYYQ@'PCC"6\ OA!8;=ZPJ@F6:\O&!KIMP40HL;QE
M9>/+*!#6-X]_BQ?*Z.8N=GRH7;C!>_0+4+-6 ?>T(!PQ1$*9PL)J .;>'_SR
M4UO<X^=^[MJ:S-87*T0 E-+PAV5,K"[M:)-+^IA3UU2@FN1H6YNZ( Q8]GOC
MNVJ&/J$Z:<9VT/8$X7'$I7QQX3,W+<L,;RAJDA3E4OS;?XP7=). ,-"RA^V9
M/0]\<UU3H0A1@BAMQL^+LM1"&!0-2L);3[^P[FOST5XOL79_N\B1<*?;7WVT
M7""L3_B[=MV&JABTY84^ F *"B_4<A0 Z5*"\'Q2@O 20!@($J+^SDVYD Q3
MWJN/NY?^ 2W_3WBP%KA#:<1]+K.5!F$\Y(KFPC9F0HD@8ZG*D 4X! G+PKL!
MM#X!3@)P&A &OL"4YL]KP KV7FUQ74KT$F_%-P"_YZN/';RMM.5("N]!MRW
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MH07T;6J "AB +E #%GXGI(!_.Y;:!\)^'OKV#U4E!YB$>YH <68XLH>U-2S
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M3A ZXF/#=!_?DP1B\]!BQQU1DLTH$4S?W734+;LHN8DPB'.W<7RF[>*.@A(
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MEN4/7(U7N"7<W&T0MJXHN=:P@COVUV)S2\8 5(]_6ULNHY /X-_6$KZ82_O
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M??J*>GK@Q/([KXZURZ)_2G/,CV)5KS<M/*&L6LM]UYOV48+P?%*"\"(@;),
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ME'&,DP1 AW)("8BQ48X ]-IU=U;/CW5AG-:&=UK#0-,<Q#LGM1;K4:1FS/:
M=6<=:MOZIV3&/IYV;O6'YRG6GC[]H+F]S;LHA\8*_&.LYE3\F )DK>F'[RZE
MI&I0@O!\TDQ .,Z2$E@>@OOQW+SRJ$6TI;9+V/AI8XXK]E&3G;9N6[!4?2_Z
MI*TH1ZAO-AW7[J1M]Y%VC#7>H9W-S<;4%B%'4/N,QSOZ ">HW3>?US<__;ZI
M =@^WD0BF7;#S1?E]X:%Z3<-^]:T$8(PBA#$.V,<VHP$$[SL_LWO_@XH)PTY
M+!0[:-H9SLGF!9YWVXEK)HT;L!*0<5XS'H*=T ?4!&K;(HDU8-S?;ZW-29_@
M^3B7,5Y&_R@XE$3@T^XC8?]0HW@MQ5J*.? >?0K^^WU<0ER[C]/P/2@2!T.I
M!<: OX___K\"X\9A41YKP\]8P^8@WCGI>@G>MO="K#OM6'O==3OIHS\+A8.V
M;ENH'6U_>)>U9DS=N32_%(.JK#?[;:DA-Y0@/)\T$Q!.2DI*2IJ.MA0EZH'O
M;QS<4T#XD[??.SCNTEL&;_S<S7/Q?.#&KPSN^/:#LV;Q3"A!."DI*6D'("#\
MW6*5?_W!AP:7WO6O@W==NWYPTE7KYN(YY]:O#N[^SO07?\P#)0@G)24E[0#T
MHZW;!M_;N'EP__<>&5S_]6\/SO[2/8.S_N'NN7@NWO"-P7T/3G_QRCQ0@G!2
M4E+2#D!;M_UDL.E'/RY O&7PC>\^/+CM6P\,;KW_.W/QW/U?_U.L_.DN29D7
M2A!.2DI*V@%(4E<]DO63P>#'DN!^O'7P?W/RL/*W/8ZDM1V9$H23DI*2DI)F
M1 G"24E)24E),Z($X:2DI*2DI!E1@G!24E)24M*,*$$X*2DI*2EI1I0@G)24
ME)24-"-*$$Y*2DI*2IH1)0@G)24E)27-B!*$DY*2DI*29D0)PDE)24E)23.B
M!.&DI*2DI*0948)P4E)24E+2C"A!."DI*2DI:4:4()R4E)24E#0C2A!.2DI*
M2DJ:$24()R4E)24ES8@2A).2DI*2DF9$"<))24E)24DSH@3AI*2DI*2D&5&"
M<%)24E)2THPH03@I*2DI*6E&E""<E)24E)0T(TH03DI*2DI*FA$E""<E)24E
M)<V($H23DI*2DI)F1 G"24E)24E),Z($X:2DI*2DI!E1@G!24E)24M*,Z/\!
4U#AX)+F"? T     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>xfor-20210611_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20210611.xsd" xlink:type="simple"/>
    <context id="icd559cc0f512485fad1a52199f605202_D20210611-20210611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-06-11</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml80L2ZyYWc6ZTJmNGQzYzk3NDhlNDEwNGIzYWMxMDM3NDljNmNjODYvdGFibGU6ZWI2YjU4ZTQxN2M5NDkzMzkyYTYzZGU5OTdhNWM5ZWEvdGFibGVyYW5nZTplYjZiNThlNDE3Yzk0OTMzOTJhNjNkZTk5N2E1YzllYV8wLTEtMS0xLTA_f32c898b-4fab-4955-9d30-16674eeef997">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml80L2ZyYWc6ZTJmNGQzYzk3NDhlNDEwNGIzYWMxMDM3NDljNmNjODYvdGFibGU6ZWI2YjU4ZTQxN2M5NDkzMzkyYTYzZGU5OTdhNWM5ZWEvdGFibGVyYW5nZTplYjZiNThlNDE3Yzk0OTMzOTJhNjNkZTk5N2E1YzllYV8xLTEtMS0xLTA_538af006-2d42-4311-bfc1-bfb0b2bb99f2">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MjIwYjJiZWZkNjM4NDBmY2I0ZjI2MTcwYjU4YTYxYjgvdGFibGVyYW5nZToyMjBiMmJlZmQ2Mzg0MGZjYjRmMjYxNzBiNThhNjFiOF8wLTEtMS0xLTA_1724a181-2472-4467-935f-90a7e498282d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18yMTg_7eee5b7d-46bf-4657-8de7-e4a56b9b97ac">2021-06-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OGJmMzJhMzljODM4NDkxYmIzMDU4OTU0OTdlN2NlMGQvdGFibGVyYW5nZTo4YmYzMmEzOWM4Mzg0OTFiYjMwNTg5NTQ5N2U3Y2UwZF8xLTAtMS0xLTA_c96eb2d8-2850-4153-a389-8ff52a6ffb32">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTAtMS0xLTA_239d9523-d848-41f7-965d-87cf7390a09f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTItMS0xLTA_4defbf91-01f8-440d-a1fa-9b4cc325bd32">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6NzJjODRiOTk5NmNjNGY2NjhlNjNhYzlhMGMzNmMzOTgvdGFibGVyYW5nZTo3MmM4NGI5OTk2Y2M0ZjY2OGU2M2FjOWEwYzM2YzM5OF8wLTQtMS0xLTA_d9489976-1e33-4574-a075-054488ab3159">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8wLTAtMS0xLTA_bfe51f4c-dc97-435e-a3c9-93d71ebe5252">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8wLTEtMS0xLTA_4bc13424-ccd0-4827-92c0-3598b0c76d64">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTAtMS0xLTA_4e5896f7-9e1b-4bbc-a3d4-a3440e313a1d">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTEtMS0xLTA_6d6097b2-297e-4f8b-98ca-b397c5024a0d">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6MWRhYjg5Yjk4OGNkNDgwMzhjNTdkY2JmMWE5ZDdkMGYvdGFibGVyYW5nZToxZGFiODliOTg4Y2Q0ODAzOGM1N2RjYmYxYTlkN2QwZl8xLTMtMS0xLTA_c0908c03-f3b2-4fb6-b372-24b81a917507">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDYy_0663326f-1ee4-4873-957e-0ea34c9dc263">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY3_8f48d04c-0e32-496c-b004-ee36e45e409e">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY5_2cef6116-a1ad-48fe-9944-d17b644e56d9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY0_41248245-eedb-4642-a324-ce9f16260566">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcx_1d5f414a-3715-418b-9d9a-d2672198bfbb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcy_324a9b4e-d402-4d34-bc37-d2fb2937a475">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTAtMS0xLTA_a554e900-945e-4a21-b5e8-86fe26289bf0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTItMS0xLTA_54f9ad6e-5a20-4691-b3a2-a60ea5d96104">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGFibGU6OTc0MWQ5YTAwOTgzNDM5NDlkYTExOWE3MmNlMTgzYmIvdGFibGVyYW5nZTo5NzQxZDlhMDA5ODM0Mzk0OWRhMTE5YTcyY2UxODNiYl8xLTQtMS0xLTA_7a92a998-5a82-4cec-ae56-21a710cb4b48">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDcz_b40ef987-974e-490e-8f53-65789b9c6be6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="icd559cc0f512485fad1a52199f605202_D20210611-20210611"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkNWZlZjUzZTdhNTRiYTViZGM0OTVhYzZkNmNiZTUyL3NlYzpiZDVmZWY1M2U3YTU0YmE1YmRjNDk1YWM2ZDZjYmU1Ml8xL2ZyYWc6MDk2MmRjMGFhNjhlNDBjNjk3MDM5NDAxMDVkZTEzOTMvdGV4dHJlZ2lvbjowOTYyZGMwYWE2OGU0MGM2OTcwMzk0MDEwNWRlMTM5M18xNDY2_e70a6b6c-af86-4940-a045-1c3182701a7d">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140706007961144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 11,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;%!+ 0(4 Q0    ( *HRRU)PSDPW[0   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *HRRU*97)PC$ 8  )PG
M   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ JC++4J8NCK-D!   ;A$  !@              ("!# @  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *HRRU*?H!OPL0(  .(,
M   -              "  :8,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MJC++4I>*NQS     $P(   L              ( !@@\  %]R96QS+RYR96QS
M4$L! A0#%     @ JC++4JK$(A8S 0  (@(   \              ( !:Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *HRRU(D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *HRRU)ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20210611.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20210611.htm">xfor-20210611.htm</File>
    <File>pressreleasejune112021.htm</File>
    <File>xfor-20210611.xsd</File>
    <File>xfor-20210611_lab.xml</File>
    <File>xfor-20210611_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20210611.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xfor-20210611.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20210611_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20210611_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20210611.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20210611",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20210611.htm",
      "contextRef": "icd559cc0f512485fad1a52199f605202_D20210611-20210611",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20210611.htm",
      "contextRef": "icd559cc0f512485fad1a52199f605202_D20210611-20210611",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-21-012055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-012055-xbrl.zip
M4$L#!!0    ( *HRRU*PK3'H?A8  -=M   :    <')E<W-R96QE87-E:G5N
M93$Q,C R,2YH=&WM75MW$SNR?C^_0@,+2-:R$]LX=X:U@A,&SA#(ALRPYVF6
MW"W;FG2WO*7N!.]??[XJJ2^^)$-@ ^;L\&!PNULM596JOKJ)9W\Y>3>X^-?Y
MJ9CD:2+.__'BS>N!>-#>WO[X=+"]?7)Q(EY=G+T1_:U.5UQ8F3F=:Y/)9'O[
M].T#\6"2Y]/#[>WKZ^NMZZ=;QHZW+]YOTU#][<08I[;B/'[P_!E=P:>2\?/_
M>?:7=EN<F*A(59:+R"J9JU@43F=C\3%6[E*TV^&N@9G.K!Y/<M'K]+KBH[&7
M^DKZWW.=)^IY.<ZS;?_]V3:_Y-G0Q+/GSV)])73\UP=Z)./=[N[!;G>GT^UW
MG^X/.[V1[,G^WK[J=_=&W7_O[&.6V[C?/^3R6:+^^B#567NB: *'!YUI?G2M
MXWQRV.UT'CW@^YX_T^E8R"3'*U(Y5O_NR*W_3,</A+/1TB4_9!ANMS?]=)1*
M.\8;AB;/37JX@Q=<*9OK2"9MF>AQ=IBK3WGX.;S[ ,_AW2,#TH41(Y,8>_BP
MPW^.Z)?V2*8ZF1T^N="I<N*MNA;O32JS)RT'!K:=LGKD;W3Z=W78[>'-_/7:
M3ZZ/<1*=J7+MW1XM^/'#[F[GZ,_S^6R;:+)"*I@KGD$LG#^('Z>_M@\.MKI+
MT_2SP1:PSS__MZ][^K_\MH)P$?:LL@N4&\KH<FQ-D<7M0,01_SFZA:0#C#>T
M^B92]A=(N;>2E+_VQ?E$VE1&JN#]Y\1QEF$B$=AU;I7#;"7I/6%&XMR0#KQ2
MXD3F4HRL2<6[;&Q(?6$0IT1W* 9X!XT#E:GQB:?.Y)6Q^I,<&2MT)C[*)%:9
MR^WCA[W^[E'Z^.%^K[MWY'!?9,TX,<."IIEJ*60N3E\=LP:\,V77CA^5:/,K
M#G6.VZ//X-![$,3E(E9D+QRX AIB\"(5K\=G1*+$7+>%S&*1ZK@=&[K%%>.Q
MPD-#?+2A9Z-$.B>F)L=:B2O$BK3!EFE28-RAA0AD>BCRB;)R.J,WQ:88)JJ=
M%D$*;N3>%+]C=/?XX<[!D4B5S" 6HR+!((V)3U3*+,8_$W6EDGJJ5L5%Q*_
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M.H7Z8ZMLP6]A%\;IULK-"^_H,'".3K76694TNZ>TU?@VMHFE0O]3:]J;-!L
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MFZ];LJ@P)S]ED!7R=D P@LX^%93"$DW-J40>9"B-P\!#OP,[?Y@79O%@N63
M/"^(VB4)R7GG"\C>1MB"$7(JV,VEP UA<I>\N2:T<IDP$P\NR&J>%&;-%N4
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MEW^G6Q:F6),O:Q&Z<0OU>R3N3NTPL.A=/LP1G;Y'U<@MHD!DK7B(@0LBSNF
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MX_S&^2;5\KL39>G"^99FW^,?#("SXDWGZ>UC%E_?Y YR$=Q]-7L5A93YOI!
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M=>)H;@Y3,7H9V:%XM+*G=QG9W\O !:55RM72TNYMQYMCH!F!+A808\!\O;+
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M>%NV>7O] 99YIT39_F;7D%DP$H@EB$B+$3?$( -*(<4!$RXX!JY&(.(YVX.
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M'.W]'U!+ 0(4 Q0    ( *HRRU*PK3'H?A8  -=M   :              "
M 0    !P<F5S<W)E;&5A<V5J=6YE,3$R,#(Q+FAT;5!+ 0(4 Q0    ( *HR
MRU*-XJ"QY10  )&0   1              "  ;86  !X9F]R+3(P,C$P-C$Q
M+FAT;5!+ 0(4 Q0    ( *HRRU(D82HC;P(  'H'   1              "
M <HK  !X9F]R+3(P,C$P-C$Q+GAS9%!+ 0(4 Q0    ( *HRRU)?YS!VZ H
M (YE   5              "  6@N  !X9F]R+3(P,C$P-C$Q7VQA8BYX;6Q0
M2P$"% ,4    " "J,LM2<LI[6/X&  "C-0  %0              @ &#.0
K>&9O<BTR,#(Q,#8Q,5]P<F4N>&UL4$L%!@     %  4 3 $  +1       $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
